Photodynamic Therapy Using HPPH in Treating Patients With Dysplasia, Cancer in Situ, or Invasive Cancer of the Larynx

This study is ongoing, but not recruiting participants.

Sponsor:

Information provided by (Responsible Party):

Roswell Park Cancer Institute

ClinicalTrials.gov Identifier:

NCT00675233

First received: May 8, 2008

Last updated: December 4, 2015

Last verified: December 2015

History of Changes

Purpose

RATIONALE: Photodynamic therapy uses a drug, such as HPPH, that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed. This may be an effective treatment for laryngeal cancer.

PURPOSE: This phase I trial is studying the side effects and best dose of laser light therapy when given together with HPPH in treating patients with dysplasia, cancer in situ, or invasive cancer of the larynx.

Condition	Intervention	Phase
Head and Neck Cancer	Drug: HPPH Procedure: laser therapy	Phase 1


Study Type:	Interventional
Study Design:	Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Phase I Trial of Photodynamic Therapy With HPPH (2-1[Hexyloxyethyl]-2-devinylpyropheophorbide-a) for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Larynx

Resource links provided by NLM:

MedlinePlus related topics: Cancer

Genetic and Rare Diseases Information Center resources: Laryngeal Cancer

U.S. FDA Resources

Further study details as provided by Roswell Park Cancer Institute:

Primary Outcome Measures:

Toxicity [ Time Frame: 6 weeks ] [ Designated as safety issue: Yes ]
Tumor response [ Time Frame: 3 months ] [ Designated as safety issue: No ]


Enrollment:	29
Study Start Date:	January 2008
Primary Completion Date:	June 2013 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Treatment PDT Patients undergo PDT comprising HPPH IV over 1 hour on day 1 followed by laser light to the tumor on day 2. At least 6 weeks later, patients achieving partial response, no response, or a geographical miss may undergo a second course of treatment.	Drug: HPPH Given IV Procedure: laser therapy Escalating light doses with 665 nm light

Detailed Description:

OBJECTIVES:

Primary

To determine the maximum tolerated dose of laser light therapy using a fixed dose of HPPH in patients with dysplasia, squamous cell carcinoma in situ, or T1 squamous cell carcinoma of the larynx.

Secondary

To determine response in patients treated with this regimen.

OUTLINE: This is a dose-escalation study of laser light therapy.

Patients undergo photodynamic therapy comprising HPPH IV over 1 hour on day 1 and laser light therapy to the tumor on day 2. Approximately 8 weeks later, patients with a partial response, no response, or a geographical miss may receive a second course of treatment.

After completion of study treatment, patients are followed at 1 week, 1 month, 3 months, and then periodically thereafter.

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS:

Biopsy-confirmed diagnosis of 1 of the following:
- Mild to severe dysplasia of the larynx
  - Dysplastic lesions > 3 mm in thickness
- Squamous cell carcinoma in situ of the larynx
- T1 squamous cell carcinoma of the larynx
  - Tumor > 3 mm in thickness
  - No T2-T4 squamous cell carcinoma of the larynx
Newly diagnosed or recurrent disease

PATIENT CHARACTERISTICS:

ECOG performance status 0-2
Total bilirubin > 2.0 mg/dL
Creatinine > 2.0 mg/dL
SGOT > 3 times upper limit of normal (ULN)
Alkaline phosphatase > 3 times ULN
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception during and for 3-6 months after completion of study treatment
No porphyria
No hypersensitivity to porphyrin or porphyrin-like compounds

PRIOR CONCURRENT THERAPY:

Any prior therapy allowed
At least 4 weeks since prior and no concurrent chemotherapy or radiotherapy

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00675233

Locations


United States, New York
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263-0001

Sponsors and Collaborators

Roswell Park Cancer Institute

Investigators


Principal Investigator:	Hassan Arshad, MD	Roswell Park Cancer Institute

More Information


Responsible Party:	Roswell Park Cancer Institute
ClinicalTrials.gov Identifier:	NCT00675233 History of Changes
Other Study ID Numbers:	CDR0000595166 RPCI-I-119207
Study First Received:	May 8, 2008
Last Updated:	December 4, 2015
Health Authority:	United States: Institutional Review Board United States: Food and Drug Administration

Keywords provided by Roswell Park Cancer Institute:


recurrent squamous cell carcinoma of the larynx stage I squamous cell carcinoma of the larynx stage III squamous cell carcinoma of the larynx stage IV squamous cell carcinoma of the larynx stage 0 laryngeal cancer

Additional relevant MeSH terms:


Head and Neck Neoplasms Neoplasms by Site Neoplasms

ClinicalTrials.gov processed this record on September 26, 2016

To Top